More Access and Evidence Articles

Access and Evidence

Considerations regarding early HTA consultation to optimize access

Izzy Gladstone, (May 10, 2018)

Access and Evidence

Considerations regarding early HTA consultation to optimize access

Izzy Gladstone, (May 10, 2018)

Access and Evidence

Explore how innovative financing schemes can help you overcome payer budget restrictions

Izzy Gladstone, (May 9, 2018)

Access and Evidence

Pressure on Prices - Dealing with a Shifting Landscape

Izzy Gladstone, (May 9, 2018)

Access and Evidence

The Pharma-Payer relationship: how will it evolve and how will you change your approach?

Izzy Gladstone, (May 9, 2018)

Access and Evidence

The Pharma-Payer relationship: how will it evolve and how will you change your approach?

Izzy Gladstone, (May 9, 2018)

Access and Evidence

Understand the benefits of putting market access at the heart of your company culture

Izzy Gladstone, (May 9, 2018)

Access and Evidence

Assessing the Value of Immuno-Oncology: Challenges & Opportunities

Izzy Gladstone, (May 9, 2018)

Access and Evidence

Ensure a best-in-class value dossier by harmonising clinical and commercial priorities

Izzy Gladstone, (May 9, 2018)

Access and Evidence

Increase your understanding of the burden of illness through text mining

Izzy Gladstone, (May 9, 2018)

Pages